Citations (53)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Letizia Carrara, Silvia Maria Lavezzi, Elisa Borella, Giuseppe De Nicolao, Paolo Magni & Italo Poggesi. (2017) Current mathematical models for cancer drug discovery. Expert Opinion on Drug Discovery 12:8, pages 785-799.
Read now
Read now
Apexa Bernard, Holly Kimko, Dinesh Mital & Italo Poggesi. (2012) Mathematical modeling of tumor growth and tumor growth inhibition in oncology drug development. Expert Opinion on Drug Metabolism & Toxicology 8:9, pages 1057-1069.
Read now
Read now
Naveen Dakappagari, Laura Neely, Shabnam Tangri, Karen Lundgren, Lori Hipolito, Annalee Estrellado, Francis Burrows & Hong Zhang. (2010) An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors. Biomarkers 15:1, pages 31-38.
Read now
Read now
Ellinor Oxelmark, Jennifer M. Roth, Peter C. Brooks, Steven E. Braunstein, Robert J. Schneider & Michael J. Garabedian. (2006) The Cochaperone p23 Differentially Regulates Estrogen Receptor Target Genes and Promotes Tumor Cell Adhesion and Invasion. Molecular and Cellular Biology 26:14, pages 5205-5213.
Read now
Read now
Articles from other publishers (49)
Abhijit Pal, Rajiv Shinde, Manuel Selvi Miralles, Paul Workman & Johann de Bono. (2021) Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development. Nature Reviews Clinical Oncology.
Crossref
Crossref
Paul Workman. 2020. HSF1 and Molecular Chaperones in Biology and Cancer. HSF1 and Molecular Chaperones in Biology and Cancer
163
179
.
Margaret S. Landis. 2017. Translating Molecules into Medicines. Translating Molecules into Medicines
297
315
.
Maria G. Chini, Nicola Malafronte, Maria C. Vaccaro, Maria J. Gualtieri, Antonio Vassallo, Michele Vasaturo, Sabrina Castellano, Ciro Milite, Antonietta Leone, Giuseppe Bifulco, Nunziatina De Tommasi & Fabrizio Dal Piaz. (2016) Identification of Limonol Derivatives as Heat Shock Protein 90 (Hsp90) Inhibitors through a Multidisciplinary Approach. Chemistry – A European Journal 22:37, pages 13236-13250.
Crossref
Crossref
Joaquin MateoJohann S. de Bono. (2016) Interrogating the Cancer Genome to Deliver More Precise Cancer Care. American Society of Clinical Oncology Educational Book:36, pages e577-e583.
Crossref
Crossref
Spiros LinardopoulosJulian Blagg. (2015) Aurora Kinase Inhibition: A New Light in the Sky?. Journal of Medicinal Chemistry 58:13, pages 5186-5188.
Crossref
Crossref
M Stroh, DG Duda, CH Takimoto, S Yamazaki & P Vicini. (2014) Translation of Anticancer Efficacy From Nonclinical Models to the Clinic. CPT: Pharmacometrics & Systems Pharmacology 3:8, pages 1-4.
Crossref
Crossref
Joaquin Mateo, Michael Ong, David S. P. Tan, Michael A. Gonzalez & Johann S. de Bono. (2013) Appraising iniparib, the PARP inhibitor that never was—what must we learn?. Nature Reviews Clinical Oncology 10:12, pages 688-696.
Crossref
Crossref
J. M. Patki & S. S. Pawar. (2013) HSP90: Chaperone-me-not. Pathology & Oncology Research 19:4, pages 631-640.
Crossref
Crossref
Stephanie M. Cohen, Ridhwi Mukerji, Abbas K. Samadi, Huiping Zhao, Brian S. J. Blagg & Mark S. Cohen. (2011) Novel C-Terminal Hsp90 Inhibitor for Head and Neck Squamous Cell Cancer (HNSCC) with in vivo Efficacy and Improved Toxicity Profiles Compared with Standard Agents. Annals of Surgical Oncology 19:S3, pages 483-490.
Crossref
Crossref
Simon Pacey, Martin Gore, David Chao, Udai Banerji, James Larkin, Sarah Sarker, Karen Owen, Yasmin Asad, Florence Raynaud, Mike Walton, Ian Judson, Paul Workman & Tim Eisen. (2010) A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Investigational New Drugs 30:1, pages 341-349.
Crossref
Crossref
Adam S. Duerfeldt & Brian S.J. Blagg. (2010) Hsp90 inhibition: Elimination of shock and stress. Bioorganic & Medicinal Chemistry Letters 20:17, pages 4983-4987.
Crossref
Crossref
Timothy A. Yap, Shahneen K. Sandhu, Paul Workman & Johann S. de Bono. (2010) Envisioning the future of early anticancer drug development. Nature Reviews Cancer 10:7, pages 514-523.
Crossref
Crossref
Xiaoping Tian, Bo Chen & Xiaochuan Liu. (2009) Telomere and Telomerase as Targets for Cancer Therapy. Applied Biochemistry and Biotechnology 160:5, pages 1460-1472.
Crossref
Crossref
Xiaoying Yin, Hong Zhang, Karen Lundgren, Lynn Wilson, Francis Burrows & Carol G. Shores. (2009) BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. International Journal of Cancer 126:5, pages 1216-1225.
Crossref
Crossref
H. Carl Le, Mihaela Lupu, Khushali Kotedia, Neal Rosen, David Solit & Jason A. Koutcher. (2009) Proton MRS detects metabolic changes in hormone sensitive and resistant human prostate cancer models CWR22 and CWR22r. Magnetic Resonance in Medicine 62:5, pages 1112-1119.
Crossref
Crossref
Daniel S. W. Tan, George V. Thomas, Michelle D. Garrett, Udai Banerji, Johann S. de Bono, Stan B. Kaye & Paul Workman. (2009) Biomarker-Driven Early Clinical Trials in Oncology. The Cancer Journal 15:5, pages 406-420.
Crossref
Crossref
Philip J. Tofilon & Kevin Camphausen. (2009) Molecular Targets for Tumor Radiosensitization. Chemical Reviews 109:7, pages 2974-2988.
Crossref
Crossref
Emmanuel Skordalakes. (2009) Telomerase structure paves the way for new cancer therapies. Future Oncology 5:2, pages 163-167.
Crossref
Crossref
Timothy A. Yap, Craig P. Carden & Stan B. Kaye. (2009) Beyond chemotherapy: targeted therapies in ovarian cancer. Nature Reviews Cancer 9:3, pages 167-181.
Crossref
Crossref
S. A. Danovi, H. H. Wong & N. R. Lemoine. (2008) Targeted therapies for pancreatic cancer. British Medical Bulletin 87:1, pages 97-130.
Crossref
Crossref
Hideyuki Onodera, Masami Kaneko, Yuichi Takahashi, Yumiko Uochi, Jun Funahashi, Takayuki Nakashima, Shiro Soga, Makoto Suzuki, Shunichi Ikeda, Yoshinori Yamashita, Endang S. Rahayu, Yutaka Kanda & Michio Ichimura. (2008) Conformational significance of EH21A1–A4, phenolic derivatives of geldanamycin, for Hsp90 inhibitory activity. Bioorganic & Medicinal Chemistry Letters 18:5, pages 1588-1591.
Crossref
Crossref
Alison H.M. Reid, Richard Baird & Paul Workman. 2008. Principles of Molecular Oncology. Principles of Molecular Oncology
317
365
.
Ian Collins, Rhoda Molife, Stan B. Kaye & Paul Workman. 2005. The Cancer Handbook. The Cancer Handbook.
Rhoda Molife, Ian Collins, Paul Workman & Stan B. Kaye. 2005. The Cancer Handbook. The Cancer Handbook.
Debashis SarkerSimon PaceyPaul Workman. (2007) Use of pharmacokinetic/pharmacodynamic biomarkers to support rational cancer drug development. Biomarkers in Medicine 1:3, pages 399-417.
Crossref
Crossref
YK Jeon, CH Park, K‐Y Kim, YC Li, J Kim, YA Kim, J‐H Paik, B‐K Park, C‐W Kim & Y‐N Kim. (2007) The heat‐shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein–Barr virus‐positive NK/T‐cell lymphoma by Akt down‐regulation. The Journal of Pathology 213:2, pages 170-179.
Crossref
Crossref
Kevin Camphausen & Philip J. Tofilon. (2007) Inhibition of Hsp90: A Multitarget Approach to Radiosensitization. Clinical Cancer Research 13:15, pages 4326-4330.
Crossref
Crossref
Sharon M. GowanAnthea HardcastleAlbert E. HallsworthMelanie R. ValentiLisa-Jane K. HunterAlexis K. de Haven BrandonMichelle D. GarrettFlorence RaynaudPaul WorkmanWynne AherneSuzanne A. Eccles. (2007) Application of Meso Scale Technology for the Measurement of Phosphoproteins in Human Tumor Xenografts. ASSAY and Drug Development Technologies 5:3, pages 391-402.
Crossref
Crossref
Qing Yao, Brenda Weigel & John Kersey. (2007) Synergism between Etoposide and 17-AAG in Leukemia Cells: Critical Roles for Hsp90, FLT3, Topoisomerase II, Chk1, and Rad51. Clinical Cancer Research 13:5, pages 1591-1600.
Crossref
Crossref
J.L. Holmes, S.Y. Sharp & P. Workman. 2007. Heat Shock Proteins in Cancer. Heat Shock Proteins in Cancer
295
330
.
Ian Collins & Paul Workman. (2006) New approaches to molecular cancer therapeutics. Nature Chemical Biology 2:12, pages 689-700.
Crossref
Crossref
Wenchang Guo, Philip Reigan, David Siegel, Joseph Zirrolli, Daniel Gustafson & David Ross. (2006) The Bioreduction of a Series of Benzoquinone Ansamycins by NAD(P)H:Quinone Oxidoreductase 1 to More Potent Heat Shock Protein 90 Inhibitors, the Hydroquinone Ansamycins. Molecular Pharmacology 70:4, pages 1194-1203.
Crossref
Crossref
Hong Zhang, Daun Chung, Yong-Ching Yang, Laura Neely, Steven Tsurumoto, Junhua Fan, Lin Zhang, Marco Biamonte, John Brekken, Karen Lundgren & Francis Burrows. (2006) Identification of new biomarkers for clinical trials of Hsp90 inhibitors. Molecular Cancer Therapeutics 5:5, pages 1256-1264.
Crossref
Crossref
H Pelicano, J S Carew, T J McQueen, M Andreeff, W Plunkett, M J Keating & P Huang. (2006) Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C. Leukemia 20:4, pages 610-619.
Crossref
Crossref
Mounia Beloueche-Babari, L. Elizabeth Jackson, Nada M.S. Al-Saffar, Suzanne A. Eccles, Florence I. Raynaud, Paul Workman, Martin O. Leach & Sabrina M. Ronen. (2006) Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells. Molecular Cancer Therapeutics 5:1, pages 187-196.
Crossref
Crossref
Wenchang Guo, Philip Reigan, David Siegel, Joseph Zirrolli, Daniel Gustafson & David Ross. (2005) Formation of 17-Allylamino-Demethoxygeldanamycin (17-AAG) Hydroquinone by NAD(P)H:Quinone Oxidoreductase 1: Role of 17-AAG Hydroquinone in Heat Shock Protein 90 Inhibition. Cancer Research 65:21, pages 10006-10015.
Crossref
Crossref
Udai Banerji, Michael Walton, Florence Raynaud, Rachel Grimshaw, Lloyd Kelland, Melani Valenti, Ian Judson & Paul Workman. (2005) Pharmacokinetic-Pharmacodynamic Relationships for the Heat Shock Protein 90 Molecular Chaperone Inhibitor 17-Allylamino, 17-Demethoxygeldanamycin in Human Ovarian Cancer Xenograft Models. Clinical Cancer Research 11:19, pages 7023-7032.
Crossref
Crossref
Anthea HardcastleKathy BoxallJuliet RichardsPeter TomlinSwee SharpPaul ClarkePaul WorkmanWynne Aherne. (2005) Solid-Phase Immunoassays in Mechanism-Based Drug Discovery: Their Application in the Development of Inhibitors of the Molecular Chaperone Heat-Shock Protein 90. ASSAY and Drug Development Technologies 3:3, pages 273-285.
Crossref
Crossref
Xiaoying Yin, Hong Zhang, Francis Burrows, Lin Zhang & Carol G. Shores. (2005)
Potent Activity of a Novel Dimeric Heat Shock Protein 90 Inhibitor against Head and Neck Squamous Cell Carcinoma
In vitro
and
In vivo
. Clinical Cancer Research 11:10, pages 3889-3896.
Crossref
Crossref
Tim H. Brümmendorf. (2005) Telomerase Activity – a Prognostic Factor in Colorectal Cancer?. Oncology Research and Treatment 28:11, pages 550-551.
Crossref
Crossref
P. WORKMAN. (2005) Drugging the Cancer Kinome: Progress and Challenges in Developing Personalized Molecular Cancer Therapeutics. Cold Spring Harbor Symposia on Quantitative Biology 70:0, pages 499-515.
Crossref
Crossref
Zong-Qiang Tian, Yaoquan Liu, Dan Zhang, Zhan Wang, Steven D. Dong, Christopher W. Carreras, Yiqing Zhou, Giulio Rastelli, Daniel V. Santi & David C. Myles. (2004) Synthesis and biological activities of novel 17-aminogeldanamycin derivatives. Bioorganic & Medicinal Chemistry 12:20, pages 5317-5329.
Crossref
Crossref
Rebecca R. Saff, Elena S. Spanjaard, Andreas M. Hohlbaum & Ann Marshak-Rothstein. (2004) Activation-Induced Cell Death Limits Effector Function of CD4 Tumor-Specific T Cells. The Journal of Immunology 172:11, pages 6598-6606.
Crossref
Crossref
Brian Dymock, Xavier Barril, Mandy Beswick, Adam Collier, Nicholas Davies, Martin Drysdale, Alexandra Fink, Christophe Fromont, Roderick E. Hubbard, Andrew Massey, Allan Surgenor & Lisa Wright. (2004) Adenine derived inhibitors of the molecular chaperone HSP90—SAR explained through multiple X-ray structures. Bioorganic & Medicinal Chemistry Letters 14:2, pages 325-328.
Crossref
Crossref
Richard Baird & Paul Workman. 2004. Principles of Molecular Oncology. Principles of Molecular Oncology
569
606
.
Martin Sattler, Patrick C. Ma & Ravi Salgia. 2004. Molecular Targeting and Signal Transduction. Molecular Targeting and Signal Transduction
121
138
.
B M Seddon & P Workman. (2003) The role of functional and molecular imaging in cancer drug discovery and development. The British Journal of Radiology 76:suppl_2, pages S128-S138.
Crossref
Crossref
Adeela Kamal, Lia Thao, John Sensintaffar, Lin Zhang, Marcus F. Boehm, Lawrence C. Fritz & Francis J. Burrows. (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425:6956, pages 407-410.
Crossref
Crossref